Article
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2013
Cohn A L, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah B Y S, Kopp M V, Sakaeva D D, Mitchell E P, Dubey S, Suzuki S, Hei Y-J, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo S-P
Abstract excerpt
BACKGROUND: Targeted agents presently available for mutant KRAS metastatic colorectal cancer (mCRC) are bevacizumab and aflibercept. We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.